MAP2K7 and cancer: We find that TP53 mutation is associated with 6 anti-cancer drugs in our analysis, including 2 MEK inhibitors, 2 RTK inhibitors, Nutlin3, and an RAF inhibitor, substantiating that TP53 plays a key role in the determinant of drug sensitivity.